The present invention relates to specific solid forms of (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl)-amide, and its hydrates and solvates. The present invention further relates to processes for preparing said solid forms, pharmaceutical compositions comprising said solid forms, and methods of using said solid forms and pharmaceutical compositions to treat disease.本發明係關於(S)-吡咯啶-1,2-二甲酸2-醯胺1-(4-甲基-5-[2-(2,2,2-三氟-1,1-二甲基-乙基)-吡啶-4-基]-噻唑-2-基)-醯胺之特定固體形式,及其水合物及溶劑合物。本發明另外係關於製備該等固體形式之製程、包含該等固體形式之醫藥組合物,及使用該等固體形式及醫藥組合物治療疾病之方法。(無元件符號說明)
